20 May 2020 - - US-based biopharmaceutical company Adjuvance Technologies has been awarded supplemental contract funding from The National Institute of Allergy and Infectious Diseases (NIAID), the company said.

The funds will be used to evaluate TQL1055, manufactured by Adjuvance, with SARS-CoV2 antigen, manufactured by NIH (National Institutes of Health).

TQL1055 is Adjuvance's novel Saponin vaccine adjuvant. The total funding in this contract is USD 1.47m.

Adjuvance Technologies is a privately held biopharmaceutical company focused on improving health and saving lives through breakthroughs in vaccine adjuvant design.

Its lead adjuvant, TQL1055, is in pre-clinical development for multiple indications in infectious disease, oncology, neurobiology, substance abuse, and allergy.

The National Institutes of Health (NIH), a part of the US Department of Health and Human Services, is the US's medical research agency.